Co-Targeting the EGFR and PI3K/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?

SIMPLE SUMMARY: Combining EGFR-targeted therapies, such as cetuximab, with a potent inhibitor of the PI3K/Akt pathway may be a novel therapeutic strategy that could potentially overcome/circumvent resistance. Interestingly, all pathways downstream of EGFR play a role in the regulation of the autopha...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaryouh, Hannah, Van Loenhout, Jinthe, Peeters, Marc, Vermorken, Jan Baptist, Lardon, Filip, Wouters, An
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776372/
https://www.ncbi.nlm.nih.gov/pubmed/36551613
http://dx.doi.org/10.3390/cancers14246128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776372/
https://www.ncbi.nlm.nih.gov/pubmed/36551613
http://dx.doi.org/10.3390/cancers14246128

Ejemplares similares